These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27094132)

  • 41. Identification of tetrahydrocarbazoles as novel multifactorial drug candidates for treatment of Alzheimer's disease.
    Honarnejad K; Daschner A; Gehring AP; Szybinska A; Giese A; Kuznicki J; Bracher F; Herms J
    Transl Psychiatry; 2014 Dec; 4(12):e489. PubMed ID: 25514752
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy.
    Zheng H; Youdim MB; Fridkin M
    ACS Chem Biol; 2010 Jun; 5(6):603-10. PubMed ID: 20455574
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A review on cholinesterase inhibitors for Alzheimer's disease.
    Anand P; Singh B
    Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.
    Farina R; Pisani L; Catto M; Nicolotti O; Gadaleta D; Denora N; Soto-Otero R; Mendez-Alvarez E; Passos CS; Muncipinto G; Altomare CD; Nurisso A; Carrupt PA; Carotti A
    J Med Chem; 2015 Jul; 58(14):5561-78. PubMed ID: 26107513
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile.
    Bautista-Aguilera ÓM; Budni J; Mina F; Medeiros EB; Deuther-Conrad W; Entrena JM; Moraleda I; Iriepa I; López-Muñoz F; Marco-Contelles J
    J Med Chem; 2018 Aug; 61(15):6937-6943. PubMed ID: 29969030
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mitochondrial Dysfunction in Neocortex and Hippocampus of Olfactory Bulbectomized Mice, a Model of Alzheimer's Disease.
    Avetisyan AV; Samokhin AN; Alexandrova IY; Zinovkin RA; Simonyan RA; Bobkova NV
    Biochemistry (Mosc); 2016 Jun; 81(6):615-23. PubMed ID: 27301290
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Int Rev Neurobiol; 2011; 100():191-215. PubMed ID: 21971009
    [TBL] [Abstract][Full Text] [Related]  

  • 49. AP39, a Mitochondria-Targeted Hydrogen Sulfide Donor, Supports Cellular Bioenergetics and Protects against Alzheimer's Disease by Preserving Mitochondrial Function in APP/PS1 Mice and Neurons.
    Zhao FL; Fang F; Qiao PF; Yan N; Gao D; Yan Y
    Oxid Med Cell Longev; 2016; 2016():8360738. PubMed ID: 27057285
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rationally designed multi-targeted agents against neurodegenerative diseases.
    Geldenhuys WJ; Van der Schyf CJ
    Curr Med Chem; 2013; 20(13):1662-72. PubMed ID: 23410161
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease.
    Chen Z; Digiacomo M; Tu Y; Gu Q; Wang S; Yang X; Chu J; Chen Q; Han Y; Chen J; Nesi G; Sestito S; Macchia M; Rapposelli S; Pi R
    Eur J Med Chem; 2017 Jan; 125():784-792. PubMed ID: 27736684
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Progress of dementia medicine: Special reference to Alzheimer's disease].
    Utsumi K
    Hokkaido Igaku Zasshi; 2014 May; 89(1):21-3. PubMed ID: 25039104
    [No Abstract]   [Full Text] [Related]  

  • 54. A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics.
    Gökhan-Kelekçi N; Yabanoğlu S; Küpeli E; Salgin U; Ozgen O; Uçar G; Yeşilada E; Kendi E; Yeşilada A; Bilgin AA
    Bioorg Med Chem; 2007 Sep; 15(17):5775-86. PubMed ID: 17611112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tacrine and its analogues impair mitochondrial function and bioenergetics: a lipidomic analysis in rat brain.
    Melo T; Videira RA; André S; Maciel E; Francisco CS; Oliveira-Campos AM; Rodrigues LM; Domingues MR; Peixoto F; Manuel Oliveira M
    J Neurochem; 2012 Mar; 120(6):998-1013. PubMed ID: 22192081
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of thienopyrrolotriazine derivatives to protect mitochondrial function against Aβ-induced neurotoxicity.
    Kim T; Son WS; Morshed MN; Londhe AM; Jung SY; Park JH; Park WK; Lim SM; Park KD; Cho SJ; Jeong KS; Lee J; Pae AN
    Eur J Med Chem; 2017 Dec; 141():240-256. PubMed ID: 29031071
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Progress in Target Drug Molecules for Alzheimer's Disease.
    Xie J; Liang R; Wang Y; Huang J; Cao X; Niu B
    Curr Top Med Chem; 2020; 20(1):4-36. PubMed ID: 31797761
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting Mitochondria in Alzheimer Disease: Rationale and Perspectives.
    Lanzillotta C; Di Domenico F; Perluigi M; Butterfield DA
    CNS Drugs; 2019 Oct; 33(10):957-969. PubMed ID: 31410665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.